Filing Flows › Health Care › Cryoport (CYRX)
Cryoport (CYRX) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Cryoport (CYRX) Q3 2026 earnings results →
Q3 2026 Revenue up 14% year over year to $50.2M · 22¢ of every $1 of revenue lost · operating margin -17.5%
Cryoport made $50.2M in Q3 2026 (+14% Y/Y): Service $28.6M, Product $21.7M. Operating margin -17.5%, net loss $10.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $50.2M in Q3 2026, up 14% year over year and up 3% from the previous quarter. BioLogistics Solutions was the largest line at 45% of revenue. BioLogistics Solutions added $3.1M year over year (up 16%), 52% of the total change.
Gross margin was 47.5%, down 0.8 points from Q3 2025. Operating costs exceeded revenue by $8.8M, an operating margin of -17.5%. Operating expenses grew 4% against revenue growth of 14%. The quarter ended with a net loss of $10.9M, wider than the previous quarter's $8.3M loss.
Operating cash flow was $5.2M (up 138% year over year). Non-cash charges added back $6.5M of depreciation and amortization and $2.3M of share-based compensation. Working capital and other items added $7.3M. Capital expenditures of $5.3M exceeded it, leaving free cash flow of −$40K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $50.2M | +14% | -17.5% | −$10.9M | $5.2M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $49.0M | +8% | -20.5% | −$8.3M | $1.1M |
| Q1 2026 | 10-Q | May 5, 2026 | $47.8M | +16% | -20.1% | −$10.5M | $3.7M |
| Q4 2025 | 10-K | Mar 5, 2026 | $45.5M | +10% | -22.1% | −$11.6M | $919K |
| Q3 2025 | 10-Q | Nov 6, 2025 | $44.2M | +15% | -22.5% | −$6.9M | $2.2M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $45.5M | +14% | -21.2% | $109M | −$7.3M |
| Q1 2025 | 10-Q | May 8, 2025 | $41.0M | +10% | -23.1% | −$12.0M | −$4.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Cryoport
We are a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with a strong focus on supporting the rapidly growing cell and gene therapy (“CGT”) market. Our solutions are purpose-built to support a broad range of global life sciences markets, including biopharmaceutical and pharmaceutical companies, the animal health markets, reproductive medicine, academic institutions, research, and government agencies. Our solutions help our customers ensure the safe, compliant storage, handling, and delivery of high value, temperature sensitive biological materials, including cell and gene therapies and immunotherapies.
In its own words, from its 10-K, filed Mar 5, 2026.
Cryoport against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +14% against the peers' median +10%. Operating margin: -17.5% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CYRX Cryoport | Q3 2026 | $50.2M | +14% | -17.5% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Cryoport 10-Q on SEC EDGAR · CIK 1124524 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns CYRX and who is buying
More on CYRX
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results